Section 13
Chapter 12,277

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

Kyriakou, C.; Thomson, K.; D'Sa, S.; Flory, A.; Hanslip, J.; Goldstone, A.H.; Yong, K.L.

British Journal of Haematology 129(6): 763-770


ISSN/ISBN: 0007-1048
PMID: 15953002
DOI: 10.1111/j.1365-2141.2005.05521.x
Accession: 012276929

Download citation:  

The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM). All 52 patients were evaluable for response with a median follow up of 18 (4-29) months.

PDF emailed within 0-6 h: $19.90